Loss of amino acids 1490Lys-Ser-Lys1492 in the COOH-terminal region of topoisomerase IIα in human small cell lung cancer cells selected for resistance to etoposide results in an extranuclear enzyme localization

Cancer Research

Volumn 57, Issue 20, 1997, Pages 4451-4454

  Wessel, Irene ^a,b   Jensen, Peter B ^b   Falck, Jacob ^a,b   Mirski, Shelagh E L ^c   Cole, Susan P C ^c   Sehested, Maxwell ^a  

^a Rigshospitalet   (Denmark)

^b FINSEN LABORATORY   (Denmark)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); ETOPOSIDE;

AMINO ACID SEQUENCE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CARBOXY TERMINAL SEQUENCE; ENZYME LOCALIZATION; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIGENS, NEOPLASM; ATP-BINDING CASSETTE TRANSPORTERS; CARCINOMA, SMALL CELL; CELL NUCLEUS; CONSENSUS SEQUENCE; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; HUMANS; ISOENZYMES; LUNG NEOPLASMS; LYSINE; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; P-GLYCOPROTEIN; PEPTIDE FRAGMENTS; POINT MUTATION; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE DELETION; SERINE; TUMOR CELLS, CULTURED;

EID: 0030774826     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Wang, J. C. DNA topoisomerases. Annu. Rev. Biochem., 65: 635-692, 1996.
2. Chen, A. Y., and Liu, L. F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34: 191-218, 1994.
3. Chen, C., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., and Roninson, I. B. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell, 47: 381-389, 1986.
4. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science (Washington DC), 258: 1650-1654, 1992.
5. Pommier, Y., Kerrigan, D., Schwartz, R. E., Swack, J. A., and McCurdy, A. Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibitors. Cancer Res., 46: 3075-3081, 1986.
6. Danks, M. K., Schmidt, C. A., Cirtain, M. C., Suttle, D. P., and Beck, W. T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochemistry, 27: 8861-8869, 1988.
7. Nitiss, J. L., and Beck, W. T. Antitopoisomerase drug action and resistance. Eur. J. Cancer, 32A: 958-966, 1996.
8. Vassetzky, V. S., Alghisi, G-C., and Gasser, S. M. DNA topoisomerase II mutations and resistance to anti-tumor drugs. BioEssays, 17: 767-774, 1995.
9. Feldhoff, P. W., Mirski, S. E. L., Cole, S. P. C., and Sullivan, D. M. Altered subcellular distribution of topoisomerase-II alpha in a drug-resistant human small cell lung cancer cell line. Cancer Res., 54: 756-762, 1994.
10. r 160,000 topoisomerase II α is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line. Cancer Res., 55: 2129-2134, 1995.
11. Harker, W. G., Slade, D. L., Parr, R. L., and Holguin, M. H. Selective use of an alternative stop codon and polyadenylation signal within intron sequences leads to a truncated topoisomerase II α messenger RNA and protein in human HL-60 leukemia cells selected for resistance to mitoxantrone. Cancer Res., 55: 4962-4971, 1995.
12. Takano, H., and Fojo, T. Acquired alternate splicing of topoisomerase IIα: a novel mechanism of resistance that defines a region of the gene with a role in nuclear translocation. Proc. Am. Assoc. Cancer Res., 36: 451, 1995.
13. Jensen, S., Andersen, A. H., Kjeldsen, E., Biersack, H., Olsen, E. H. N., Andersen, T. B., Westergaard, O., and Jakobsen, B. K. Analysis of functional domain organization in DNA topoisomerase II from humans. Mol. Cell. Biol., 16: 3866-3877, 1996.
14. Jensen, P. B., Christensen, I. J., Sehested, M., Hansen, H. H., and Vindeløv, L. L. Differential cytotoxicity of 19 anticancer agents in wild type and etoposide resistant small cell lung cancer cell lines. Br. J. Cancer, 67: 311-320, 1993.
15. Brock, I., Hipfner, D. R., Nielsen, B. S., Jensen, P. B., Deeley, R. G., Cole, S. P. C., and Sehested, M. Sequential co-expression of the multidrug resistance genes, MRP and mdr1, and their products in VP-16 (etoposide) selected H69 small cell lung cancer cells. Cancer Res., 55: 459-462, 1995.
16. Deffie, A. M., Batra, J. K., and Goldenberg, G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res., 49: 58-62, 1989.
17. Sehested, M., and Jensen, P. B. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem. Pharmacol., 51: 879-886, 1996.
18. Crenshaw, D. G., and Hsieh, T-s. Function of the hydrophilic carboxyl terminus of type II DNA topoisomerase from Drosophila melanogaster. II. In vivo studies. J. Biol. Chem., 268: 21335-21343, 1993.
19. Dingwall, C., and Laskey, R. A. Nuclear targeting sequences: a consensus? Trends Biochem. Sci., 16: 478-481, 1991.
20. Yu, Q., Mirski, S. E. L., Sparks, K. E., and Cole, S. P. C. Two COOH-terminal truncated cytoplasmic forms of topoisomerase II α in a VP-16-selected lung cancer cell line result from partial gene deletion and alternative splicing. Biochemistry, 36: 5968-5877, 1997.